Retraction
The role of apatinib combined with paclitaxel (aluminum binding type) in platinum-resistant ovarian cancer
Paper Information
Record ID:
26054
Author(s):
Publication Date:
September 21, 2020
Retraction Date:
February 19, 2021
(4.7 years years ago)
Subjects:
Institutions:
- Department of Biochemistry and Molecular Biology, Basic Medical College, Shanxi Medical University, No. 56 Xinjian South Road, Yingze District, Taiyuan City, Shanxi Province, China
- Department of Gynecology, Shanxi Cancer Hospital, Taiyuan, China
- Shanxi province center for disease control and prevention, Taiyuan, China
- The Second Affiliated Hospital of Shanxi Medical University, Taiyuan, China
Country:
🇨🇳 ChinaArticle Type:
Publisher:
Springer - Biomed Central (BMC)
Open Access:
Yes
PubMed ID:
Retraction PubMed ID:
Retraction Details
Citations (8)
8
Total Citations6
Post-Retraction(75.0%)
0
Pre-Retraction1
Same DayPost-Retraction Citation Analysis
0
Within 30 days
3
Within 1 year
2
After 2+ years
1046
Days since retraction (latest)
Heavy Metals Removal Using Carbon Based Nanocomposites
Unknown Authors
Unknown Journal
Published: Unknown
Efficacy and safety of combined anlotinib-oral etoposide treatment for patients with platinum-resistant ovarian cancer
Shuai Huang, Gui-Hua Sheng, Qiubo Lv et al. (7 authors)
Journal of Gynecologic Oncology
Open Access
Published: Jan 2024
2 citations
2 citations
1046 days after retraction
Efficacy and safety of apatinib combined with liposomal doxorubicin or paclitaxel versus liposomal doxorubicin or paclitaxel monotherapy in patients with recurrent platinum‐resistant ovarian cancer
Hailei Yang, Aizhi Geng, Zhenfeng Wang et al. (4 authors)
Journal of Obstetrics and Gynaecology Research
Published: Mar 2023
4 citations
4 citations
768 days after retraction
Self-emulsifying System Co-loaded with Paclitaxel and Coix Seed Oil Deeply Penetrated to Enhance Efficacy in Cervical Cancer
Yunyan Chen, Shaozhen Wang, Qiyan Hu et al. (4 authors)
Current Drug Delivery
Open Access
Published: Jun 2022
19 citations
19 citations
494 days after retraction
Apatinib and Ginsenoside-Rb1 Synergetically Control the Growth of Hypopharyngeal Carcinoma Cells
Yanwei Li, Feng He, Yu Zhang et al. (4 authors)
Disease Markers
Open Access
Published: Jan 2022
9 citations
9 citations
328 days after retraction
A Comparison of Chemotherapy Used with and without Apatinib for Patients with Ovarian Carcinoma Who Progressed after Standard Regimens: A Systematic Review and Meta-Analysis
Chao Hou, Zhuang-Zhuang Jiang, Bo Pan et al. (5 authors)
Evidence-based Complementary and Alternative Medicine
Open Access
Published: Nov 2021
3 citations
3 citations
257 days after retraction
Naphtho-γ-pyrone Dimers from an Endozoic <i>Aspergillus niger</i> and the Effects of Coisolated Monomers in Combination with Cisplatin on a Cisplatin-Resistant A549 Cell Line
Yun-Wei Hu, Ying Liu, Er‐Yan Guo et al. (10 authors)
Journal of Natural Products
Published: Jun 2021
3 citations
3 citations
123 days after retraction
Retraction Note: The role of apatinib combined with paclitaxel (aluminum binding type) in platinum-resistant ovarian cancer
Hong Zhao, Rong Li, Xiaoyan Wang et al. (9 authors)
Journal of Ovarian Research
Open Access
Published: Feb 2021
3 citations
3 citations
Same day as retraction
Quick Stats
Total Citations:
12
Years Since Retraction:
4.7 years
Open Access:
Yes
Last Checked:
Jul 24, 2025